Abstract
Background: Epithelioid hemangio-endothelioma (EHE) is a rare malignant tumor of vascular origin that electively metastasizes to lungs and liver. Case report: We report the case of a 51-year-old woman with metastatic and progressive EHE of the liver. She was successfully treated with daily administration of sunitinib malate, an oral multi-target tyrosine kinase inhibitor, which particularly targets vascular endothelial growth factor (VEGF) receptors. Stabilization has lasted 6 years. We discuss the rationale for using antiangiogenic treatment for EHE. Conclusion: This case adds to a growing body of evidence that suggests that antiangiogenic agents should be considered in patients who present with advanced EHE.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Weiss SW, Goldblum JR: Hemangioendothelioma: Vascular tumors of intermediate malignancy; in: Weiss SW, Goldblum JR (eds): Enzinger and Weiss's Soft Tissue Tumors, 5th ed. PA, Mosby, 2008, pp. 681-702.
2.
Weiss SW, Ishak KG, Dail DH, et al.: Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 1986;3:259-287.
[PubMed]
3.
Fletcher C (ed): Organization classification of tumours pathology and genetics of tumours of soft tissue and bone. Lyon, IARC, 2002.
4.
Roudier-Pujol C, Enjolras O, Lacronique J, et al.: [Multifocal epithelioid hemangioendothelioma with partial remission after interferon alfa-2a treatment]. Ann Dermatol Venereol 1994;121:898-904.
[PubMed]
5.
Idilman R, Dokmeci A, Beyler AR, et al.: Successful medical treatment of an epithelioid hemangioendothelioma of liver. Oncology 1997;54:171-175.
[PubMed]
6.
Holley M P, Cuschieri A: Epithelioid haemangioendothelioma of the liver: Objective response to hepatic intra-arterial 5-FU. Eur J Surg Oncol 1989;15:73-78.
[PubMed]
7.
Emamaullee JA, Edgar R, Toso C, et al.: Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management. Liver Transpl 2010;16:191-197.
[PubMed]
8.
Cardinal J, de Vera ME, Marsh JW, et al.: Treatment of hepatic epithelioid hemangioendothelioma: A single-institution experience with 25 cases. Arch Surg 2009;144:1035-1039.
[PubMed]
9.
Mehrabi A, Kashfi A, Fonouni H, et al.: Primary malignant hepatic epithelioid hemangioendothelioma: A comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006;107:2108-2121.
[PubMed]
10.
Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010;22:351-355.
[PubMed]
11.
George S, Merriam P, Maki RG, et al.: Multicenter phase II trial of sunitinib in the treatment of non-gastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-3160.
[PubMed]
12.
Tolkach Y, Petrov S, Lerut E, Van Poppel H: Epithelioid hemangioendothelioma of the kidney treated with sunitinib. Onkologie 2012;35:376-378.
[PubMed]
13.
Agulnik M, Yarber JL, Okuno SH, et al.: An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257-263.
[PubMed]
14.
van der Graaf WT, Blay JY, Chawla S P, et al.: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-1886.
[PubMed]
© 2014 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
